ReShape Lifesciences Inc, a provider of weight loss solutions, has entered into a definitive merger agreement with Obalon Therapeutics Inc, a company focused on developing and commercializing novel technologies for weight loss.
Under the terms of the merger agreement that has been unanimously approved by the boards of directors of both companies, existing ReShape stockholders will have majority ownership of the combined company immediately following the closing of the merger and Obalon will be renamed ReShape Lifesciences Inc. The current directors and officers of ReShape will comprise the board of directors and executive management of the combined company.
“We are excited with this opportunity to add Obalon’s FDA approved Balloon System to ReShape’s line of minimally invasive weight-loss solutions while also expanding our market reach. Our portfolio also includes the Lap-Band, emerging products that support bariatric surgical procedures across the spectrum and ReShapeCare, which is our reimbursed, telehealth-based patient support program that is available for any medically supervised weight loss program. This integration positions us to achieve our goals for growth and continued advancement towards becoming the premier weight loss company for physicians and patients.”
— Bart Bandy, President and Chief Executive Officer of ReShape
[Source(s): ReShape Lifesciences Inc, BioSpace]
Obalon Announces First Patient Treatments at its First Company-Owned Center for Weight Loss
Obalon Receives Two New Patents for its Balloon System
Gas-Filled Balloon Device Is Safe, Effective for Weight Loss, Per Study